Longeveron Inc.

Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the

Maxim Group analyst Michael Okunewitch downgrades Longeveron (NASDAQ:LGVN) from Buy to Hold.

Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationDMC performed a risk-benefit assessment, identified no new

The Company intends to submit to the FDA a Sponsor Statistical Analysis Plan (SAP) for ELPIS II with a composite primary endpoint and secondary endpoints for the FDA's review and approval, and remains optimistic that the trial results and other available evidence will be sufficient to support filing a Biologics License Application (BLA) following the readout of top-line results of the ELPIS

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $10 to $8.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1721484/000121390026042461/ea0285827-s1_longeveron.htm

China Patent No. 2026031300230720, entitled "Potency Assay," provides Longeveron with patent rights in China through 2041, assuming all annuity fees are paid.